COMP <GO>
MEDP vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Medpace Holdings Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MEDP 5
— JNJ 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MEDP
LAST: $652.01 (-3.77%) • MKT CAP: $18.95B
roic
27.90%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MEDP VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MEDP | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 27.90% | 25.50% | +2.40 | MEDP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.0x | 18.5x | +15.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.60% | 2.97% | +0.63 | MEDP | /fcf-yield <GO> |
| Operating Margin | 21.10% | 34.70% | -13.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 17.80% | 28.50% | -10.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 6.00% | +14.00 | MEDP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.13 | 5.59 | +3.54 | MEDP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | MEDP | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.6 | 60.4 | -5.73 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.08 | -0.08 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.3x | 23.0x | +12.30 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.95B | $662.49B | -$643.54B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MEDP REV | JNJ REV | MEDP GROSS % | JNJ GROSS % | MEDP FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $94.19B | 44.0% | 67.9% | $681.9M | $19.70B |
| FY 2024 | $2.11B | $88.82B | 44.0% | 69.1% | $572.3M | $19.84B |
| FY 2023 | $1.89B | $85.16B | 44.0% | 44.0% | $348.5M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MEDP // BETA 1.00
JNJ // BETA 1.08